NAMS
Price
$27.87
Change
+$0.09 (+0.32%)
Updated
Aug 21 closing price
Capitalization
3.33B
80 days until earnings call
Intraday BUY SELL Signals
ROIV
Price
$36.30
Change
-$0.54 (-1.47%)
Updated
Aug 21 closing price
Capitalization
26.22B
85 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

NAMS vs ROIV

NAMS vs ROIV Comparison Chart in %
View a ticker or compare two or three
VS
NAMS vs. ROIV commentary
Aug 23, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is NAMS is a Hold and ROIV is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 23, 2026
Stock price -- (NAMS: $27.87 vs. ROIV: $36.30)
Brand notoriety: NAMS and ROIV are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: NAMS: 37% vs. ROIV: 95%
Market capitalization -- NAMS: $3.33B vs. ROIV: $26.22B
NAMS [@Biotechnology] is valued at $3.33B. ROIV’s [@Biotechnology] market capitalization is $26.22B. The market cap for tickers in the [@Biotechnology] industry ranges from $138.91B to $0. The average market capitalization across the [@Biotechnology] industry is $2.34B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

NAMS’s FA Score shows that 1 FA rating(s) are green whileROIV’s FA Score has 1 green FA rating(s).

  • NAMS’s FA Score: 1 green, 4 red.
  • ROIV’s FA Score: 1 green, 4 red.
According to our system of comparison, both NAMS and ROIV are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

NAMS’s TA Score shows that 3 TA indicator(s) are bullish while ROIV’s TA Score has 2 bullish TA indicator(s).

  • NAMS’s TA Score: 3 bullish, 5 bearish.
  • ROIV’s TA Score: 2 bullish, 5 bearish.
According to our system of comparison, NAMS is a better buy in the short-term than ROIV.

Price Growth

NAMS (@Biotechnology) experienced а +3.30% price change this week, while ROIV (@Biotechnology) price change was +0.28% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +3.69%. For the same industry, the average monthly price growth was +15.94%, and the average quarterly price growth was +3349.70%.

Reported Earning Dates

NAMS is expected to report earnings on Nov 11, 2026.

ROIV is expected to report earnings on Nov 16, 2026.

Industries' Descriptions

@Biotechnology (+3.69% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ROIV($26.2B) has a higher market cap than NAMS($3.33B). ROIV YTD gains are higher at: 67.281 vs. NAMS (-20.553). NAMS has higher annual earnings (EBITDA): -214.95M vs. ROIV (-1.28B). ROIV has more cash in the bank: 4.29B vs. NAMS (636M). NAMS has less debt than ROIV: NAMS (23K) vs ROIV (107M). NAMS has higher revenues than ROIV: NAMS (22.6M) vs ROIV (8.26M).
NAMSROIVNAMS / ROIV
Capitalization3.33B26.2B13%
EBITDA-214.95M-1.28B17%
Gain YTD-20.55367.281-31%
P/E RatioN/A1.97-
Revenue22.6M8.26M274%
Total Cash636M4.29B15%
Total Debt23K107M0%
TECHNICAL ANALYSIS
Technical Analysis
NAMSROIV
RSI
ODDS (%)
N/A
N/A
Stochastic
ODDS (%)
Bullish Trend 3 days ago
76%
Bearish Trend 3 days ago
78%
Momentum
ODDS (%)
Bearish Trend 3 days ago
52%
Bearish Trend 3 days ago
80%
MACD
ODDS (%)
Bullish Trend 3 days ago
69%
Bullish Trend 3 days ago
84%
TrendWeek
ODDS (%)
Bullish Trend 3 days ago
65%
Bullish Trend 3 days ago
77%
TrendMonth
ODDS (%)
Bearish Trend 3 days ago
65%
Bullish Trend 3 days ago
79%
Advances
ODDS (%)
Bullish Trend 5 days ago
81%
Bullish Trend 6 days ago
78%
Declines
ODDS (%)
Bearish Trend 21 days ago
77%
Bearish Trend 3 days ago
71%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
74%
Bearish Trend 3 days ago
79%
Aroon
ODDS (%)
Bearish Trend 3 days ago
85%
Bearish Trend 3 days ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
NAMS
Daily Signal:
Gain/Loss:
ROIV
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
CSM88.600.41
+0.46%
ProShares Large Cap Core Plus
ERY9.020.04
+0.45%
Direxion Daily Energy Bear 2X ETF
NXUS24.64N/A
N/A
Nuveen International Aggregate Bond ETF
TAIL10.31-0.04
-0.43%
Cambria Tail Risk ETF
PYPU43.25-1.19
-2.69%
Direxion Daily PYPL Bull 2X Shares

NAMS and

Correlation & Price change

A.I.dvisor indicates that over the last year, NAMS has been loosely correlated with PTGX. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if NAMS jumps, then PTGX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NAMS
1D Price
Change %
NAMS100%
+0.32%
PTGX - NAMS
43%
Loosely correlated
+2.41%
IMVT - NAMS
42%
Loosely correlated
+0.05%
PTCT - NAMS
41%
Loosely correlated
-0.99%
VKTX - NAMS
40%
Loosely correlated
-1.37%
ROIV - NAMS
40%
Loosely correlated
-1.47%
More

ROIV and

Correlation & Price change

A.I.dvisor indicates that over the last year, ROIV has been loosely correlated with IMVT. These tickers have moved in lockstep 63% of the time. This A.I.-generated data suggests there is some statistical probability that if ROIV jumps, then IMVT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ROIV
1D Price
Change %
ROIV100%
-1.47%
IMVT - ROIV
63%
Loosely correlated
+0.05%
IMTX - ROIV
45%
Loosely correlated
+4.44%
KURA - ROIV
43%
Loosely correlated
+1.54%
AXON - ROIV
43%
Loosely correlated
+2.20%
ABUS - ROIV
41%
Loosely correlated
+9.22%
More